Castle Biosciences (CSTL) News Today → Was the Great Financial Crisis fun? (From Brooks Enterprises) (Ad) Free CSTL Stock Alerts $23.15 +0.12 (+0.52%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 6:14 AM | americanbankingnews.comDerek J. Maetzold Sells 2,368 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockJune 6 at 7:54 AM | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $55,411.20 in StockJune 5 at 8:00 PM | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,368 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the company's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $23.40, for a total value of $55,411.20. Following the completion of the sale, the insider now owns 57,893 shares of the company's stock, valued at $1,354,696.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link.May 30, 2024 | businesswire.comCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceMay 29, 2024 | businesswire.comNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisMay 18, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $34.22 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,585,673 shares of the company'sMay 15, 2024 | businesswire.comCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceMay 14, 2024 | finance.yahoo.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 14, 2024 | businesswire.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 10, 2024 | finance.yahoo.comCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"May 10, 2024 | businesswire.comCastle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”May 8, 2024 | finance.yahoo.comLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultMay 7, 2024 | finance.yahoo.comWall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should KnowMay 5, 2024 | finance.yahoo.comEarnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 5, 2024 | msn.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Price Target Raised to $34.00 at Robert W. BairdRobert W. Baird boosted their price target on shares of Castle Biosciences from $33.00 to $34.00 and gave the company an "outperform" rating in a research report on Friday.May 3, 2024 | businesswire.comDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckMay 2, 2024 | investorplace.comCSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comCastle Biosciences earnings: here's what Wall Street expectsMay 2, 2024 | finance.yahoo.comCastle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...May 2, 2024 | businesswire.comCastle Biosciences Reports First Quarter 2024 ResultsApril 30, 2024 | finance.yahoo.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 30, 2024 | businesswire.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 29, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Trading 6.3% Higher Castle Biosciences (NASDAQ:CSTL) Trading 6.3% HigherApril 27, 2024 | investing.comCastle Biosciences CEO Derek Maetzold sells shares worth over $22,000April 27, 2024 | seekingalpha.comCSTL Castle Biosciences, Inc.April 21, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Has $2.29 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Knights of Columbus Asset Advisors LLC boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 99.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 106,262 shares of the company's stock after purchasing an additionaApril 20, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Trims Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 542,874 shares of the companyApril 18, 2024 | investing.comCastle Biosciences CEO sells over $100k in company stockApril 18, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,947 Shares of StockApril 17, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $39,621.45 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,947 shares of the firm's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the sale, the insider now owns 65,418 shares of the company's stock, valued at approximately $1,331,256.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.April 17, 2024 | finance.yahoo.comWe're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash BurnApril 11, 2024 | businesswire.comCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024April 11, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 2,400 SharesApril 10, 2024 | finance.yahoo.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | businesswire.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | finance.yahoo.comCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | businesswire.comCastle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | investing.comCastle Biosciences director sells over $440k in company stockApril 9, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 9,152 SharesApril 6, 2024 | marketbeat.comTritonpoint Wealth LLC Buys Shares of 94,356 Castle Biosciences, Inc. (NASDAQ:CSTL)Tritonpoint Wealth LLC purchased a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 94,356 shares of the company's stock, valued at apApril 6, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,368 Shares of StockApril 5, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $51,385.60 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the company's stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $21.70, for a total value of $51,385.60. Following the completion of the transaction, the insider now owns 67,365 shares in the company, valued at approximately $1,461,820.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.April 5, 2024 | finance.yahoo.comWhat Makes Castle Bioscience (CSTL) a Prospective Investment?April 4, 2024 | finance.yahoo.comPresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerApril 4, 2024 | businesswire.comPresentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerMarch 31, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Increase in Short InterestCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,420,000 shares, an increase of 17.4% from the February 29th total of 1,210,000 shares. Based on an average daily volume of 252,100 shares, the short-interest ratio is presently 5.6 days.March 27, 2024 | businesswire.comCastle Biosciences Announces Updates to its Board of DirectorsMarch 26, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Up 5.4%Castle Biosciences (NASDAQ:CSTL) Trading Up 5.4%March 25, 2024 | finance.yahoo.comCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Was the Great Financial Crisis fun? (Ad)The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red. Get those kind of results during the Great Financial Crisis, without having to study more CSTL Media Mentions By Week CSTL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.870.73▲Average Medical News Sentiment CSTL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼43▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Genetron News Myriad Genetics News Fortrea News Veracyte News Viridian Therapeutics News CareDx News Fulgent Genetics News Celcuity News Sera Prognostics News Biodesix News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored